Charles Duncan

Laura Chico

Esther Rajavelu

Ken Cacciatore

Marc Goodman

Paul Choi

Tim Lugo

Vamil Divan

Chris Raymond

Alley Bratzel

Christopher Joseph

Douglas Tsao

Jeff Hung

Kenneth Cacciatore

Kyuwon Choi

- The Portnoy Law Firm is advising investors of **Biohaven Ltd.** (NYSE: BHVN) regarding a class action lawsuit for securities purchased between **March 24, 2023, and May 14, 2025**.  **[1935979_61cf863521fd491ea224a7be577068d1_0]** 
- Investors have until **September 12, 2025**, to file a lead plaintiff motion.  **[1935979_61cf863521fd491ea224a7be577068d1_0]** 
- The lawsuit alleges that Biohaven made false or misleading statements and/or failed to disclose material facts regarding the regulatory prospects of **troriluzole** for spinocerebellar ataxia (SCA) and the efficacy and clinical potential of **BHV-7000** for bipolar disorder.  **[1935979_61cf863521fd491ea224a7be577068d1_0]** 
- Significant stock price declines followed disclosures, including a **23%** drop on **July 27, 2023**, after the FDA refused to review troriluzole's New Drug Application, a **14%** fall on **March 3, 2025**, after BHV-7000's trial failed to statistically separate from the comparator, and over **15%** on **April 25, 2025**, after the withdrawal of troriluzole's European application.  **[1935979_61cf863521fd491ea224a7be577068d1_1]**  The stock also fell more than **19%** on **May 14, 2025**, when the FDA extended the Prescription Drug User Fee Act (PDUFA) date for troriluzole.  **[1935979_61cf863521fd491ea224a7be577068d1_1]**

Biohaven Investors Advised on Class Action Lawsuit

- A class action lawsuit has been filed against **Biohaven Ltd.** (NYSE: BHVN) on behalf of investors who purchased securities between **March 24, 2023, and May 14, 2025**.  **[1935979_90278c38d4ba4ddb90cedb2e226aaa82_0]** 
- The lawsuit alleges that Biohaven and its executives made false or misleading statements regarding the regulatory prospects of **troriluzole** for spinocerebellar ataxia (SCA) and the efficacy of **BHV-7000** for bipolar disorder.  **[1935979_90278c38d4ba4ddb90cedb2e226aaa82_0]** 
- Key disclosures cited in the complaint include the FDA's refusal to review the NDA for troriluzole in July 2023, leading to a **nearly 23%** stock drop, and the failure of BHV-7000 clinical trial data in March 2025, causing a **nearly 14%** stock decline.  **[1935979_90278c38d4ba4ddb90cedb2e226aaa82_0]** 
- Further stock price drops occurred in April 2025 (over **15%**) due to the withdrawal of troriluzole's Marketing Authorization Application in Europe, and in May 2025 (more than **19%**) when the FDA extended the PDUFA date for troriluzole.  **[1935979_90278c38d4ba4ddb90cedb2e226aaa82_0]** **[1935979_90278c38d4ba4ddb90cedb2e226aaa82_1]** 
- Investors have until **September 12, 2025**, to file a lead plaintiff motion in the class action lawsuit.  **[1935979_90278c38d4ba4ddb90cedb2e226aaa82_0]**

Biohaven Faces Class Action Lawsuit Over Drug Candidate Disclosures

- **Biohaven Ltd.** partnered with **Merus N.V.** in **January 2025** to co-develop **three new bispecific antibody drug conjugates (BsADCs)**, leveraging their respective technologies.  **[1935979_f64f6318bad24b35bf954e4ad702214d_2]** 
- The bispecific antibody drug conjugate (BsADC) market is experiencing rapid growth, with over **100** BsADCs currently in clinical trials and the first availability expected by **2029**.  **[1935979_f64f6318bad24b35bf954e4ad702214d_0]** **[1935979_f64f6318bad24b35bf954e4ad702214d_1]** 
- Recent advancements in the BsADC space include **AVZO-1418/DB-1418** receiving IND approval in **May 2025** and initiating Phase 1/2 trials in **July 2025**  **[1935979_f64f6318bad24b35bf954e4ad702214d_1]** , and **Izalontamab Brengitecan** showing encouraging Phase 1 results and advancing to Phase 3 trials.  **[1935979_f64f6318bad24b35bf954e4ad702214d_2]**

Biohaven Announces Collaboration for Bispecific ADC Development

- Faruqi & Faruqi, LLP is investigating potential claims against **Biohaven Ltd. (NYSE: BHVN)** for alleged violations of federal securities laws.  **[1935979_b8ca9480b68f42059de6032b496af20e_1]** 
- The complaint asserts that Biohaven made false or misleading statements and/or failed to disclose information regarding the regulatory prospects of **troriluzole** for spinocerebellar ataxia (SCA) and the efficacy of **BHV-7000** for bipolar disorder.  **[1935979_b8ca9480b68f42059de6032b496af20e_1]** 
- The class period for investors who suffered losses exceeding **$50,000** is between **March 24, 2023**, and **May 14, 2025**.  **[1935979_b8ca9480b68f42059de6032b496af20e_0]** 
- On **May 14, 2025**, Biohaven announced an extension of the PDUFA date for troriluzole, which led to a **19.53%** drop in the company's stock price on **May 15, 2025**.  **[1935979_b8ca9480b68f42059de6032b496af20e_1]** 
- The deadline for investors to seek the role of lead plaintiff in the federal securities class action is **September 12, 2025**.  **[1935979_b8ca9480b68f42059de6032b496af20e_1]**

Biohaven Faces Federal Securities Class Action Lawsuit

- Class action lawsuits have been filed against **Biohaven Ltd.** (BHVN) and **Neogen Corporation** (NEOG).  **[1935979_5a44cf059199408182449975635410ba_0]** 
- For **Biohaven Ltd.**, the class period is **March 24, 2023 – May 14, 2025**, with allegations of overstated regulatory prospects for troriluzole and overstated efficacy for BHV-7000.  **[1935979_5a44cf059199408182449975635410ba_0]**  The lead plaintiff deadline is **September 12, 2025**.  **[1935979_5a44cf059199408182449975635410ba_0]** 
- For **Neogen Corporation**, the class period is **January 5, 2023 – June 3, 2025**, with allegations concerning inefficiencies in the 3M integration impacting financials.  **[1935979_5a44cf059199408182449975635410ba_0]**  The lead plaintiff deadline is **September 16, 2025**.  **[1935979_5a44cf059199408182449975635410ba_0]**

Class Action Lawsuits Filed Against Biohaven Ltd. and Neogen Corporation

- Pomerantz LLP has filed a class action lawsuit against **Biohaven Ltd.** and certain officers, alleging violations of federal securities laws.  **[1935979_92623dd0a7284bbaba2934d79123cc4d_0]** 
- The lawsuit covers a class period from **March 24, 2023, to May 14, 2025**, claiming false and misleading statements were made regarding the regulatory prospects of **troriluzole** and the efficacy of **BHV-7000**.  **[1935979_92623dd0a7284bbaba2934d79123cc4d_0]** **[1935979_92623dd0a7284bbaba2934d79123cc4d_1]** 
- Key events cited include the **FDA's rejection of the troriluzole NDA** in July 2023, disappointing data for BHV-7000 in March 2025, the **withdrawal of the troriluzole MAA from the EMA** in April 2025, and the **extension of the PDUFA date** for the troriluzole NDA in May 2025, which led to stock price declines.  **[1935979_92623dd0a7284bbaba2934d79123cc4d_1]** 
- Investors who acquired Biohaven securities during the class period have until **September 12, 2025**, to seek appointment as Lead Plaintiff.  **[1935979_92623dd0a7284bbaba2934d79123cc4d_0]**

Biohaven (BHVN)